• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

自然杀伤细胞和嵌合抗原受体修饰 NK-92 细胞在肿瘤免疫治疗中的当前应用。

Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy.

机构信息

School of Medicine, Huaqiao University, Quanzhou 362021, Fujian, China.

出版信息

Int J Mol Sci. 2019 Jan 14;20(2):317. doi: 10.3390/ijms20020317.

DOI:10.3390/ijms20020317
PMID:30646574
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6358726/
Abstract

Natural killer (NK) cells are innate immune cells that can be activated rapidly to target abnormal and virus-infected cells without prior sensitization. With significant advancements in cell biology technologies, many NK cell lines have been established. Among these cell lines, NK-92 cells are not only the most widely used but have also been approved for clinical applications. Additionally, chimeric antigen receptor-modified NK-92 cells (CAR-NK-92 cells) have shown strong antitumor effects. In this review, we summarize established human NK cell lines and their biological characteristics, and highlight the applications of NK-92 cells and CAR-NK-92 cells in tumor immunotherapy.

摘要

自然杀伤 (NK) 细胞是先天免疫细胞,无需预先致敏即可快速激活以靶向异常和病毒感染的细胞。随着细胞生物学技术的重大进展,已经建立了许多 NK 细胞系。在这些细胞系中,NK-92 细胞不仅应用最广泛,而且已经获得临床批准。此外,嵌合抗原受体修饰的 NK-92 细胞(CAR-NK-92 细胞)已显示出强大的抗肿瘤作用。在这篇综述中,我们总结了已建立的人 NK 细胞系及其生物学特性,并强调了 NK-92 细胞和 CAR-NK-92 细胞在肿瘤免疫治疗中的应用。

相似文献

1
Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy.自然杀伤细胞和嵌合抗原受体修饰 NK-92 细胞在肿瘤免疫治疗中的当前应用。
Int J Mol Sci. 2019 Jan 14;20(2):317. doi: 10.3390/ijms20020317.
2
Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.工程嵌合抗原受体-自然杀伤细胞用于癌症免疫治疗。
Immunotherapy. 2020 Jun;12(9):653-664. doi: 10.2217/imt-2019-0139. Epub 2020 May 21.
3
2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.2B4 共刺激结构域增强了抗 CD5 嵌合抗原受体工程化自然杀伤细胞对 T 细胞恶性肿瘤的细胞毒性。
J Hematol Oncol. 2019 May 16;12(1):49. doi: 10.1186/s13045-019-0732-7.
4
Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.药物上调癌胚抗原表达增强了嵌合抗原受体 NK-92MI 基因修饰自然杀伤细胞对结直肠癌细胞的细胞毒性作用。
BMC Immunol. 2018 Aug 3;19(1):27. doi: 10.1186/s12865-018-0262-z.
5
Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.嵌合抗原受体自然杀伤细胞为基础的"现货"急性髓系白血病免疫疗法的合适自然杀伤细胞来源的临床前评估。
Hum Gene Ther. 2019 Apr;30(4):381-401. doi: 10.1089/hum.2018.247. Epub 2019 Mar 18.
6
Purinergic targeting enhances immunotherapy of CD73 solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells.嘌呤能靶向增强猪源 Bac 工程嵌合抗原受体自然杀伤细胞治疗 CD73 实体瘤的免疫疗法。
J Immunother Cancer. 2018 Dec 4;6(1):136. doi: 10.1186/s40425-018-0441-8.
7
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.嵌合抗原受体表达的自然杀伤细胞用于癌症的免疫治疗。
Front Immunol. 2018 Feb 15;9:283. doi: 10.3389/fimmu.2018.00283. eCollection 2018.
8
DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.用于NK细胞肿瘤免疫治疗的基于DAP12的激活型嵌合抗原受体
J Immunol. 2015 Apr 1;194(7):3201-12. doi: 10.4049/jimmunol.1400330. Epub 2015 Mar 4.
9
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.嵌合抗原受体工程化自然杀伤细胞用于癌症免疫治疗。
J Hematol Oncol. 2020 Dec 7;13(1):168. doi: 10.1186/s13045-020-00998-9.
10
Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.结直肠癌患者中 NKG2D CAR mRNA 修饰的自然杀伤细胞过继转移。
Mol Ther. 2019 Jun 5;27(6):1114-1125. doi: 10.1016/j.ymthe.2019.03.011. Epub 2019 Mar 20.

引用本文的文献

1
Advances in bioengineered CAR T/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology-based strategies for enhanced CAR T/NK cell therapy.用于胶质母细胞瘤的生物工程化嵌合抗原受体T细胞/自然杀伤细胞疗法的进展:克服免疫抑制及基于纳米技术增强嵌合抗原受体T细胞/自然杀伤细胞疗法的策略
Bioeng Transl Med. 2024 Aug 31;10(2):e10716. doi: 10.1002/btm2.10716. eCollection 2025 Mar.
2
Antitumor effects of natural killer cells derived from gene-engineered human-induced pluripotent stem cells on hepatocellular carcinoma.基因工程人诱导多能干细胞来源的自然杀伤细胞对肝细胞癌的抗肿瘤作用
Cancer Immunol Immunother. 2025 Feb 4;74(3):99. doi: 10.1007/s00262-025-03940-5.
3

本文引用的文献

1
Natural killer cells and other innate lymphoid cells in cancer.自然杀伤细胞和癌症中的其他固有淋巴细胞。
Nat Rev Immunol. 2018 Nov;18(11):671-688. doi: 10.1038/s41577-018-0061-z.
2
Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.人诱导多能干细胞来源的嵌合抗原受体修饰自然杀伤细胞增强抗肿瘤活性。
Cell Stem Cell. 2018 Aug 2;23(2):181-192.e5. doi: 10.1016/j.stem.2018.06.002. Epub 2018 Jun 28.
3
First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.
Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects.
将诱导多能干细胞(iPSC)技术与基于嵌合抗原受体(CAR)的免疫疗法相结合:最新进展、挑战与未来前景。
Front Cell Dev Biol. 2024 Nov 18;12:1491282. doi: 10.3389/fcell.2024.1491282. eCollection 2024.
4
CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside.嵌合抗原受体自然杀伤细胞治疗胃肠道肿瘤免疫治疗:从基础到临床。
Mol Cancer. 2024 Oct 23;23(1):237. doi: 10.1186/s12943-024-02151-3.
5
Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia.在基于细胞的免疫疗法中寻找潜在的靶点,以应对急性髓系白血病的挑战。
Front Immunol. 2024 Sep 30;15:1460437. doi: 10.3389/fimmu.2024.1460437. eCollection 2024.
6
Enhanced non-viral gene delivery via calcium phosphate/DNA co-precipitates with low-voltage pulse electroporation in NK-92 cells for immunocellular therapy.通过磷酸钙/DNA共沉淀物与低电压脉冲电穿孔增强非病毒基因递送用于NK-92细胞的免疫细胞治疗。
APL Bioeng. 2024 Aug 6;8(3):036107. doi: 10.1063/5.0198191. eCollection 2024 Sep.
7
Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy.超越 CAR-T:CAR-NK 细胞疗法在哮喘免疫治疗中的兴起。
J Transl Med. 2024 Aug 5;22(1):736. doi: 10.1186/s12967-024-05534-8.
8
Immune Regulation and Immune Therapy in Melanoma: Review with Emphasis on CD155 Signalling.黑色素瘤中的免疫调节与免疫治疗:重点关注CD155信号传导的综述
Cancers (Basel). 2024 May 21;16(11):1950. doi: 10.3390/cancers16111950.
9
Natural killer cell-related anti-tumour adoptive cell immunotherapy.自然杀伤细胞相关抗肿瘤过继细胞免疫治疗。
J Cell Mol Med. 2024 Jun;28(11):e18362. doi: 10.1111/jcmm.18362.
10
Tri-specific killer engager: unleashing multi-synergic power against cancer.三特异性杀伤细胞衔接器:释放对抗癌症的多重协同力量。
Explor Target Antitumor Ther. 2024;5(2):432-448. doi: 10.37349/etat.2024.00227. Epub 2024 Apr 25.
CAR NK-92细胞的首次人体临床试验:CD33-CAR NK-92细胞在复发难治性急性髓系白血病患者中的安全性测试。
Am J Cancer Res. 2018 Jun 1;8(6):1083-1089. eCollection 2018.
4
Natural killer cell specificity for viral infections.自然杀伤细胞对病毒感染的特异性。
Nat Immunol. 2018 Aug;19(8):800-808. doi: 10.1038/s41590-018-0163-6. Epub 2018 Jul 19.
5
Reprogramming human T cell function and specificity with non-viral genome targeting.利用非病毒基因组靶向技术重新编程人类 T 细胞的功能和特异性。
Nature. 2018 Jul;559(7714):405-409. doi: 10.1038/s41586-018-0326-5. Epub 2018 Jul 11.
6
Natural killer cell cytotoxicity and its regulation by inhibitory receptors.自然杀伤细胞细胞毒性及其受抑制性受体的调节。
Immunology. 2018 Jul;154(3):383-393. doi: 10.1111/imm.12921. Epub 2018 Apr 11.
7
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.嵌合抗原受体表达的自然杀伤细胞用于癌症的免疫治疗。
Front Immunol. 2018 Feb 15;9:283. doi: 10.3389/fimmu.2018.00283. eCollection 2018.
8
Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.嵌合抗原受体肿瘤免疫治疗的改革:重定向自然杀伤细胞。
Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):200-215. doi: 10.1016/j.bbcan.2018.01.005. Epub 2018 Jan 31.
9
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy.一项针对自体造血细胞移植后复发的难治性血液系统恶性肿瘤的NK-92细胞I期试验显示了安全性和疗效证据。
Oncotarget. 2017 Jul 12;8(51):89256-89268. doi: 10.18632/oncotarget.19204. eCollection 2017 Oct 24.
10
FDA Approves Second CAR T-cell Therapy.美国食品药品监督管理局批准第二种嵌合抗原受体T细胞疗法。
Cancer Discov. 2018 Jan;8(1):5-6. doi: 10.1158/2159-8290.CD-NB2017-155. Epub 2017 Nov 7.